厄妥索单抗 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "厄妥索单抗" in Chinese language version.

refsWebsite

Global rank Chinese rank

4web.archive.org

1^st place

1^st place

low place

low place

4^th place

5^th place

5^th place

12^th place

2^nd place

23^rd place

1creativebiolabs.net

low place

low place

1clinicaltrials.gov

5,225^th place

4,888^th place

clinicaltrials.gov

ClinicalTrials.gov: Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy. [2024-01-23]. （原始内容存档于2016-04-10）.

creativebiolabs.net

Ertumaxomab Overview - Creative Biolabs. www.creativebiolabs.net. [2024-01-23].

doi.org

Kiewe, Philipp; Thiel, Eckhard. Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert Opinion on Investigational Drugs. 2008-10, 17 (10) [2024-01-23]. ISSN 1744-7658. PMID 18808314. doi:10.1517/13543784.17.10.1553. （原始内容存档于2024-04-12）.

fresenius.com

ASCO-Meeting: Fresenius Biotech presents clinical trial results of new antibodies at the world's largest cancer convention | FSE. www.fresenius.com. [2024-01-23]. （原始内容存档于2024-01-23）（英语）.
2009 Consolidated Financial Statements and Management Report of Fresenius SE (PDF). [2016-03-20]. （原始内容 (PDF)存档于2016-03-31）.

nih.gov

pubmed.ncbi.nlm.nih.gov

Kiewe, Philipp; Thiel, Eckhard. Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert Opinion on Investigational Drugs. 2008-10, 17 (10) [2024-01-23]. ISSN 1744-7658. PMID 18808314. doi:10.1517/13543784.17.10.1553. （原始内容存档于2024-04-12）.

ncbi.nlm.nih.gov

Kiewe, Philipp; Thiel, Eckhard. Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert Opinion on Investigational Drugs. 2008-10, 17 (10) [2024-01-23]. ISSN 1744-7658. PMID 18808314. doi:10.1517/13543784.17.10.1553. （原始内容存档于2024-04-12）.

web.archive.org

Kiewe, Philipp; Thiel, Eckhard. Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert Opinion on Investigational Drugs. 2008-10, 17 (10) [2024-01-23]. ISSN 1744-7658. PMID 18808314. doi:10.1517/13543784.17.10.1553. （原始内容存档于2024-04-12）.
ASCO-Meeting: Fresenius Biotech presents clinical trial results of new antibodies at the world's largest cancer convention | FSE. www.fresenius.com. [2024-01-23]. （原始内容存档于2024-01-23）（英语）.
ClinicalTrials.gov: Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy. [2024-01-23]. （原始内容存档于2016-04-10）.
2009 Consolidated Financial Statements and Management Report of Fresenius SE (PDF). [2016-03-20]. （原始内容 (PDF)存档于2016-03-31）.

worldcat.org

Kiewe, Philipp; Thiel, Eckhard. Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert Opinion on Investigational Drugs. 2008-10, 17 (10) [2024-01-23]. ISSN 1744-7658. PMID 18808314. doi:10.1517/13543784.17.10.1553. （原始内容存档于2024-04-12）.